

SPINE SAFETY CAUTIONARY NOTICE:

**Information for Healthcare Professionals:
Neurontin (gabapentin) Capsules, Tablets and Oral Solution:
Adverse Reactions – Labeling Changes**

According to MedWatch, FDA notified healthcare professionals that the ADVERSE REACTIONS text for Neurontin (gabapentin) has been updated. The following has been added to the labeling:##

ADVERSE REACTIONS

Postmarketing and Other Experience

- breast enlargement

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm249683.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.